ADT 061

ADT 061 is a **novel small molecule inhibitor of phosphodiesterase 10A (PDE10A)**, developed as a non-COX inhibitory derivative of sulindac, with selective activity against PDE10A. It is being studied primarily for the **prevention and treatment of colon neoplasms**, specifically colorectal cancer and adenomas. ADT 061 potently inhibits the growth of colon cancer cells overexpressing PDE10A by competitively blocking this enzyme, which leads to activation of cGMP/protein kinase G (PKG) signaling, phosphorylation of oncogenic β-catenin, inhibition of Wnt-induced nuclear translocation of β-catenin, and suppression of TCF/LEF transcription—all of which suppress colon tumorigenesis. Importantly, ADT 061 does not significantly inhibit other PDE isozymes at concentrations effective in cancer cells, and was found to be well-tolerated in mouse models with high local concentrations in colon mucosa and without discernable toxicity[1][3][5][7].

Other names

MCI-030MCI030MCI 030ADT 061ADT061ADT-061